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The Unblazed Trail: Bioinformatics and the Protection 
of Genetic Knowledge∗ 
Lawrence M. Sung, Ph.D.** 
INTRODUCTION 
The history of the endeavor to understand the human condition, 
fueled in part by the desire to prolong or otherwise enhance the 
enjoyment of life, will mark this year with great significance. On 
February 12, 2001, the world awoke to the news sensation of the 
achievement of a milestone in genetic knowledge arguably unrivaled 
by any other previously.1 The scientific research teams dedicated to 
 
 ∗ Copyright © 2001 by Lawrence M. Sung, Ph.D. This Article was prepared for the 
2001 Heart of America Intellectual Property Law Conference: Intellectual Property, Digital 
Technology, and Electronic Commerce co-sponsored by Washington University School of 
Law on April 6-7, 2001. 
 ** Assistant Professor of Law, University of Maryland School of Law (Baltimore, MD). 
J.D., cum laude, The American University, Washington College of Law (Washington, DC); 
Ph.D. Microbiology, U.S. Department of Defense, Uniformed Services University of the Health 
Sciences (Bethesda, Maryland); B.A. Biology, University of Pennsylvania. Former judicial 
clerk to the Honorable Raymond C. Clevenger, III, The U.S. Court of Appeals for the Federal 
Circuit (Washington, DC). All inquiries and/or comments are welcome by telephone at 
410.706.1052, or e-mail at lsung@law.umaryland.edu. 
 1. See, e.g., Scientists Set to Announce Major Advances in Mapping the Human Genome 
(Early Edition, CNN television broadcast, Feb. 12, 2001) ([I]n just three hours, were going to 
hear what could be the beginning of a revolution in the practice of medicine. An announcement 
regarding the mapping of all the genes in the human body will be made in Washington.); 
Human Genome Decoded (Today, NBC television broadcast, Feb. 12, 2001) (This morning 
details on what may be the most amazing scientific accomplishment ever, the mapping of the 
human genome. Last June, scientists on competing teams announced they had done it, and 
today they are releasing their results, and it could revolutionize the future of medical care.); 
Map of Human Genome Debuts with Some Big Surprises (World News This Morning, ABC 
television broadcast, Feb. 12, 2001) (History will have to judge, of course, but scientists say 
they may be at a turning point comparable to Copernicus figuring out the layout of the solar 
system or Darwin beginning to understand how plants and animals evolved.); Two Rival 
Studies Offer the First Detailed Look at Most of the Human Genetic Code (The Early Show, 
CBS television broadcast, Feb. 12, 2001). 
Weve been trying in the 20th century to try to treat disease without even knowing 
what the parts were, without knowing what was wrong in diseases like diabetes or 
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the elucidation of the precise structural nature of the chemicals that 
encode the design of the human organism announced the release of 
their long anticipated findingsthe nucleotide sequence of the 
human genome.2 
For even the most casual observers, the accomplishment 
underlying this report was earthshaking.3 Even for those who had 
closely monitored the progress of this project throughout its years of 
intensive effort, the publication of the human genome sequence was 
no less heralded. Indeed, the editors of Science, one of the two 
leading scientific journals to report this data, pronounced it a 
 
asthma or hypertension. Itd be like bringing your car to an auto mechanic who didnt 
know what was under the hood, didnt know the parts. 
Id.; see also Clive Cookson, A Glimpse of the Secrets of Life: The Results of the Human 
Genome Project Show Unexpected Layers of Complexity in our Genes, FIN. TIMES (LONDON), 
Feb. 12, 2001, at 21. 
Eight months ago, Bill Clinton and Tony Blair linked up to proclaim one of sciences 
greatest achievements: decoding the human genome or book of life. But that public 
relations spectacular was not supported by research data or conclusions. This week 
scientists get their first look at the evidence, with the official publication of the human 
genome sequence in the journals Nature and Science. 
Id.; China on Par With Developed Countries in Genome Research, XINHUA DAILY NEWS 
SERVICE, Feb. 12, 2001. 
The latest map and preliminary conclusion on the human genome by experts from 
China and five developed countries indicate China is on a par with the developed 
countries in this field . . . . [T]he progress, unveiled late Monday by international 
sciences news weekly Science and Nature, is the result of international cooperation. 
The research demonstrates the strength of China, the only developing country allowed 
to join the project, in this advanced research field . . . . 
Id. 
 2. See Elizabeth Pennisi, The Human Genome, 291 SCIENCE 1177, 1178 (2001):  
Just obtaining the sequence is a phenomenal achievement, one that many researchers 
did not believe possible 15 years ago . . . . Spelling out the entire sequence, all 3 billion 
or so chemical letters that make up DNA along each chromosome, would fill tomes 
equivalent to 200 New York City phone books . . . . Perhaps most humbling of all is 
the finding . . . that humans have 32,000 genes, give or take a few thousand. 
 3. See Leslie Roberts, Controversial From the Start, 291 SCIENCE 1182, 1182 (2001): 
The human genome: the crown jewel of 20th century biology, heralded at the White 
House, plastered on the covers of countless magazinesand at last spelled out today in 
intricate detail in both Science and Nature. Deciphering this string of 3 billion As, 
Ts, Gs, and Cs is being hailed as an achievement that will usher in a new era of 
biology and even alter our understanding of who we are. 
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historic moment for the scientific endeavor.4 The message to the 
scientific community, however, also appeared to reflect a tenor of 
underlying concern. 
Humanity has been given a great gift. With the completion of 
the human genome sequence, we have received a powerful tool 
for unlocking the secrets of our genetic heritage and for finding 
our place among the other participants in the adventure of 
life . . . . 
It should be no surprise that an achievement so stunning, and 
so carefully watched, has created new challenges for the 
scientific venture.5 
To be sure, the process of discovering our genetic code, from its 
inception, has fostered coincident public scrutiny and concern, which 
included portents of privacy loss, genetic discrimination, and 
eugenics.6 Perhaps most controversial, however, were the issues of 
ownership and exclusivity obtainable through patent protection to 
aspects of the human genome.7 The public debate aside, the federal 
 
 4. See Barbara R. Jasny & Donald Kennedy, Editorial: The Human Genome, 291 
SCIENCE 1153, 1153 (2001) (commemorating the contemporaneous publications of the human 
genome sequence in Science by J. Craig Venter et al. of Celera Genomics, a private enterprise, 
and in Nature by the International Human Genome Sequencing Consortium, a publicly-funded 
international cooperative of laboratories led by Francis Collins). 
 5. See id. (indicating that access to all the data needed to verify conclusions and 
protection against piracy [to] enable other proprietary data to be published after peer review 
are important considerations). 
 6. See Jeremy A. Colby, An Analysis of Genetic Discrimination Legislation Proposed by 
the 105th Congress, 24 AM. J.L. & MED. 443, 443-44 (1998). 
[G]enetic information may also result in a world characterized by genetic 
discrimination and genetic determinism. Although genetic information will be used to 
develop revolutionary treatments, such as gene therapy and other molecular medicine, 
it will also bring genetic discrimination and heretofore unrealized invasions into the 
privacy of our genetic codes. 
Id. 
 7. See Eliot Marshall, Sharing the Glory, Not the Credit, 291 SCIENCE 1189, 1191 (2001) 
(reporting the stern reaction by scientists to the negotiations between Celera and Science of a 
balanced plan, requiring Celera to release data freely to academics but allowing the company to 
protect its database by requiring readers to obtain access at a company site and register as 
academic or commercial users). Of course, the U.S. patent system has supporters and 
detractors alike as a general proposition. Nevertheless, its significance, positive or negative, to 
the business community appears clear. See John R. Allison & Mark A. Lemley, Taking Stock: 
The Law and Economics of Intellectual Property Rights: Who’s Patenting What? An Empirical 
Washington University Open Scholarship
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courts, principally the Court of Appeals for the Federal Circuit,8 and 
the U.S. Patent and Trademark Office (USPTO), attempted to provide 
guidance on the intellectual property rights that might impact such 
matters involving the human genome and other genetic data. These 
efforts, however, met with, at best, lackluster support from patent law 
practitioners and other commentators, as well as the general public.9 
In recent days, public debate in this regard focused on the proper 
scope, if any, of patent protection for genetic discoveries generally 
and for expressed sequence tags (ESTs) and single nucleotide 
polymorphisms (SNPs) specifically. Two concerns prevail. The first 
relates to the challenge, pursuant to the written description 
requirement of the patent law, to patent coverage of inventions 
pertaining to genes or gene fragments where the applicant failed to 
disclose the corresponding nucleotide sequence information. The 
second involves whether isolated and purified nucleic acid fragments 
with no known association or other functionality can satisfy the 
patent law requirement of utility as well as written description. 
 
Exploration of Patent Prosecution, 53 VAND. L. REV. 2099, 2100 (2000). 
Patents are big business. Individuals and companies are obtaining far more patents 
today than ever before. Some simple calculations make it clear that companies are 
spending over $5 billion a year obtaining patents in the U.S.to say nothing of the 
costs of obtaining patents elsewhere, and of licensing and enforcing the patents. There 
are a number of reasons why patenting is on the rise; primary among them are a 
booming economy and a shift away from manufacturing and capital-intensive 
industries towards companies with primarily intellectual assets. But whatever the 
reason, it is evident that many companies consider patents important. 
Id. 
 8. The Federal Circuit has exclusive jurisdiction of appeals in civil actions across the 
country that arise under the patent statutes. See 28 U.S.C. § 1295 (1994) (vesting the Federal 
Circuit with exclusive jurisdiction in patent appeals from final judgments and orders of the U.S. 
district courts and the U.S. Court of Federal Claims, from decisions of the Board of Patent 
Appeals and Interferences of the U.S. Patent and Trademark Office, from decisions of the 
Commissioner of Patents and Trademarks, and from decisions of the U.S. International Trade 
Commission); see also S. REP. NO. 275, at 2 (1981), reprinted in 1982 U.S.C.C.A.N. 11, 12 
(describing the legislative rationale behind the establishment of the Federal Circuit with the 
enactment of the Federal Courts Improvement Act of 1982, Pub. L. No. 97-164, 96 Stat. 25, 37 
(codified as amended at 28 U.S.C. § 1295 (1994)). 
 9. See Jerry Knight, Biotech Stocks Tougher to Unravel Than Genome, WASH. POST, 
Feb. 19, 2001, at E01 (warning about investment in biotechnology companies because [t]heir 
science is so complex, their business strategies so unpredictable, their path to profitability so 
uncertainto say nothing of so longthat its impossible to calculate what each stock is worth or 
which is better to buy). 
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Given the reactive nature of the patent system, particularly in a 
technical art such as biotechnology, where the law today deals with 
the potentially decades old science, the legal issues center on early 
research work in recombinant protein production and genomics.10 
With the human genome sequence in hand now, scientists and other 
interested members of the public recognize that the practical 
applications will likely include better, faster, and cheaper routes to 
drug discovery and advances in medical practice.11 This progress 
depends in large part on other scientific fields, that of bioinformatics 
(once better known as computational biology) and proteomics.12 The 
 
 10. See Courtney J. Miller, Patent Law and Human Genomics, 26 CAP. U. L. REV. 893, 
984 (1997). 
The genomics industry is a complex and frustrating combination of philanthropy and 
commercialism, science and law. The basic premise of sequencing the human genome 
is that such a venture will benefit humankind, but the importance of protecting the 
significant financial and physical investments required to sustain the effort have 
resulted in the need for definitive federal legislative guidelines concerning the 
intellectual property generated as the genomics industry matures. 
Id. 
 11. See Sara Dastgheib-Vinarov, A Higher Nonobviousness Standard for Gene Patents: 
Protecting Biomedical Research from the Big Chill, 4 MARQ. INTELL. PROP. L. REV. 143, 158-
59 (2000). 
In the new millenium, computational and molecular techniques allow scientists to 
accomplish what was once deemed impossible. Some of these techniques include 
designing optimum DNA probes for PCR and comparing three-dimensional protein 
secondary structure of various species with their mRNA sequences on a computer. 
These techniques, which reduce experiment times from days to minutes, have made 
most traditional molecular biological procedures obsolete. 
Id.; Lawrence M. Sung & Don J. Pelto, Bioinformatics May Get Boost From “State Street,” 
NATL L.J., Oct. 19, 1998, at C28. 
How quickly scientists achieve these goals thus may depend little on the breakneck 
pace at which they undertake to obtain new DNA sequence information by brute force. 
Indeed, the smart money is now focusing on how long it takes to understand what the 
exploding storehouses of genetic information actually teach. The true race is not to see 
who first maps every last stretch of human DNA, but who can most successfully 
identify candidates for effective drug and gene therapy based on genetic information 
with little, if any, known biological significance. 
Id. 
 12. See Mark J. Stewart, The Written Description Requirement of 35 U.S.C. § 112(1): The 
Standard After Regents of the University of California v. Eli Lilly & Co., 32 IND. L. REV. 537, 
555 n.153 (1999) (The development of bioinformatics is beginning to manage the increasing 
amount of genetic sequence information that is becoming available. Bioinformatics provides 
ways to analyze DNA and protein sequences and make predictions regarding structure or 
Washington University Open Scholarship
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legal ramifications of intellectual property protection in this 
developing research area will probably take years to manifest, but 
might engender as much, if not more, public debate than that 
presently observable with biotechnology patents.13 
This Article begins with a review of the legal treatment of 
biotechnology patents involving genetic information and addresses 
contemporary issues facing the federal courts and the USPTO. A 
consideration follows regarding the likely patent protection scenarios 
 
function relationships.) (citing ANDREAS D. BAXEVANIS & B.F. OUELLETTE, 
BIOINFORMATICS: A PRACTICAL GUIDE TO THE ANALYSIS OF GENES AND PROTEINS (1st ed. 
1998)); Ronald Cass et al., Advances in Biomaterials and Devices, and Their Financing, 6 B.U. 
J. SCI. & TECH. L. 2, 6 (2000). 
How bioinformatics and genetic engineering become important is that one can use 
information from the human genome project. The idea is then to use this information 
to help predict what functions other proteins or other regions of proteins are involved 
innot only cellular adhesion but also other cellular roles such as cell death, growth, 
and migration and differentiation. 
Id.; David Malakoff & Robert F. Service, Genomania Meets the Bottom Line, 291 SCIENCE 
1193, 1201 (2001) (Toolmakers, information suppliers, and discovery companies are already 
looking beyond genomics to proteomics, the latest effort to demystify the functions of the 
proteins coded for by all those genes. Surveying genes is a good way of finding possible drug 
targets, the reasoning goes.); Stanley Fields, Proteomics in Genomeland, 291 SCIENCE 1221, 
1221 (2001) (In the wonderland of complete sequences, there is much that genomics cannot 
do, and so the future belongs to proteomics: the analysis of complete complements of 
proteins.). 
 13. See Rebecca S. Eisenberg, Genetics and the Law: The Ethical, Legal, and Social 
Implications of Genetic Technology and Biomedical Ethics: Intellectual Property at the Public-
Private Divide: The Case of Large-Scale cDNA Sequencing, 3 U. CHI. L. SCH. ROUNDTABLE 
557, 565 (1996). 
Despite the growth of the public database, the private databases remain significantly 
larger. Inasmuch as all the information that enters the public database promptly 
becomes available in the private databases as well, the public database can never 
contain more information than the private databases. The private database owners also 
claim to offer superior products in that they have assembled contiguous fragments into 
longer sequences, they provide more complete annotations for the sequences, 
including information about expression in different types of tissue, they provide 
sequence information from customized cDNA libraries derived from tissue types of 
interest to their subscribers, and their sequence information comes with high-powered 
bioinformatics capabilities and user-friendly software. Ironically, Mercks investment 
in enhancing the public database may have enhanced the value of the private databases 
as a resource for discovery, not only by contributing further data to make the 
information in the private databases more complete, but also by creating a deluge of 
information that enhances the value of the complementary proprietary bioinformatics 
capabilities that the private database owners offer to their clients.  
Id. (internal citations omitted). 
https://openscholarship.wustl.edu/law_journal_law_policy/vol8/iss1/10
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surrounding bioinformatics and proteomics. The Article concludes 
with various proposals for the enhancement of progress in 
bioinformatics and proteomics, and other beneficiary research fields 
of genomics, through the securing of intellectual property rights.14 
I 
The protection of genetic information under patent law raises 
several issues. A prominent issue concerns the characterization of 
nucleic acids as basic research tools, to which easy access is 
considered vital to the progress of science.15 With knowledge of a 
particular nucleotide sequence, a scientist can engage in further 
experimentation, including a determination of whether that sequence 
is physically present in a sample, as well as whether transcription or 
translation products corresponding to that sequence are produced. In 
addition, nucleic acids of consequence can be used to construct 
recombinant proteins. In this sense, as structural components, nucleic 
acids can be used to facilitate further discovery. There is another 
facet to the character of nucleic acids.  
Beyond its nature as a chemical compound, a nucleic acid serves 
as a storage medium for biological information.16 The nucleotide 
sequence alone can provide an understanding of the relative 
significance of the specific nucleic acid and the products it encodes. 
As such, the genetic knowledge a nucleic acid contains can be as 
 
 14. See Emanuel Vacchiano, It’s A Wonderful Genome: The Written-Description 
Requirement Protects The Human Genome From Overly-Broad Patents, 32 J. MARSHALL L. 
REV. 805, 830 (1999). 
Congress and the biotech community must consider implementing a special patent 
category for patents to human DNA segments where a medical or industrial utility is 
not demonstrated. This special patent category would award a limited term based on a 
diminished examination process. For example, a five-year term can be appropriate for 
these patents, although such a determination requires considerable comment from the 
biotech community before implementation. 
Id. 
 15. See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The 
Anticommons in Biomedical Research, 280 SCIENCE 698 (1998). 
 16. See R.C. Lewontin, In the Beginning Was the Word, 291 SCIENCE 1263, 1263 (2001) 
(reviewing LILY E. KAY, WHO WROTE THE BOOK OF LIFE? (2000), and noting her examination 
of how the view that DNA is information that is written in a language whose words are 
in code has driven the research program and claims of molecular biology). 
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inseparable from the discrete chemical compound as a personality is 
from the human individual. 
This knowledge creates a problem, however, because intellectual 
property law is not intended to vest ownership in information per se. 
The essence of nucleic acids as both chemical compounds and 
information reservoirs, therefore, fosters a dichotomy that the patent 
law, in particular, is ill-equipped to reconcile. If patent protection to 
nucleic acids was accorded based solely on their chemical character, 
for example, claims might be issued that would be arguably 
overbroad.17 The fundamental inquiry remains whether the discoverer 
of a certain isolated and purified nucleic acid provides the public with 
knowledge worthy of the reward of a temporary right of exclusivity. 
The USPTO and federal courts have addressed the patentability of 
genetic discoveries.18 Until relatively recently, all were situations in 
which the patent applicant disclosed the genetic knowledge in 
conjunction with the chemical structure.19 In these cases, the public 
 
 17. Assuming arguendo the inevitability of such unreasonable patent claims, then various 
remedies can be proposed to ameliorate the detrimental effects. Among such notions are an 
expanded infringement exemption for pure academic, or otherwise non-commercial, research 
similar to the fair use defense under copyright law. Cf. Julie E. Cohen & Mark A. Lemley, 
Patent Scope and Innovation in the Software Industry, 89 CAL. L. REV. 1, 18 (2001) 
(recognizing that presently the patent statute includes no express provision allowing reverse 
engineering, nor is there any judicially-developed exception akin to copyrights fair use 
doctrine that might permit it). Another possibility is a broader infringement exemption for 
experimental use. Cf. id. at 29 (noting that although the patent statute itself contains only a 
narrow experimental use defense . . . [under 35 U.S.C. § 271(e)] there is also a non-statutory 
exception for experimental uses). A third option is compulsory licensing. In recent days, 
compulsory licensing issues have arisen in the international context of government-sanctioned 
generic substitutes for patented AIDS medicines. See Jon Jeter, Trial Opens in South Africa 
AIDS Drug Suit, WASH. POST, Mar. 6, 2001, at A01 (reporting on the lawsuit brought by thirty-
nine foreign drug manufacturers in Pretoria High Court to block any action pursuant to the 1997 
South African statute, the Medicines Control Act, which authorizes South Africas health 
minister to control the import and pricing of AIDS medications, irrespective of existing patent 
rights). 
 18. See, e.g., In re Mayne, 104 F.3d 1339 (Fed. Cir. 1997); In re Alton, 76 F.3d 1168 
(Fed. Cir. 1996); In re Goodman, 11 F.3d 1046 (Fed. Cir. 1993); In re Bell, 991 F.2d 781 (Fed. 
Cir. 1993); In re Vaeck, 947 F.2d 488 (Fed. Cir. 1991); In re OFarrell, 853 F.2d 894 (Fed. Cir. 
1988).  
 19. See, e.g., Monsanto Co. v. Mycogen Plant Science, Inc., 261 F.3d 1356 (Fed. Cir. 
2001) (concerning claims reciting the introduction into plants of recombinant DNA known to 
make them more resistant to insects by genetic modification to express a Bacillus thuringiensis 
protein, which is toxic to various insects); Singh v. Brake, 222 F.3d 1362 (Fed. Cir. 2000) 
(involving the appellate review of an interference proceeding before the USPTO Board of 
Patent Appeals and Interferences concerning a DNA construct known to relate to alpha-factor, 
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benefit rationale underlying the patent system is arguably satisfied
the public is taught the what, why, when, where, and how of the 
biological significance as well as the chemical structure of the 
patented nucleic acid. By contrast, more recent patent applications to 
some genetic discoveries, such as ESTs and SNPs, disclose little, if 
any, corresponding genetic knowledge.20 The present controversy 
over patenting genes generally appears to center on these certain 
inventions that are accompanied by minimal disclosure of associative 
or functional biological relevance. 
In any event, the advent and increasing precision of technologies 
like bioinformatics and proteomics might better facilitate the 
patentability of gene fragments randomly isolated from samples. 
Even where no known association or function can be ascribed to it 
upon isolation, a nucleic acid might begin to impart such knowledge 
with the aid of predictive modeling available through bioinformatics 
and proteomics.21 Accordingly, perhaps the controversy over 
patenting genes that derive from concerns over ESTs and SNPs will 
subside as the state of the art progresses, allowing scientists to 
recognize meaning in the otherwise bare nucleotide sequences.22 
 
also known as alpha-mating factor, which is a peptide released by the budding yeast 
Saccharomyces cerevisiae when a haploid cell is prepared to mate); Schering Corp. v. Amgen 
Inc., 222 F.3d 1347 (Fed. Cir. 2000) (involving recombinant DNA molecules known to encode 
specific types of human interferon). 
 20. See infra note 115. 
 21. Of course, fans and critics alike can find support in their positions on the relative 
success of computer predictive modeling, as evidenced in many other fields such as seismic and 
weather forecasting. See More Quakes Ahead for Pacific Northwest? (Mar. 1, 2001), at 
http://www.cnn.com/2001/TECH/science/03/01/quake.folo/index.html. (Will another powerful 
earthquake rip through western Washington State or the region after Wednesdays big one? 
Despite considerable improvements in seismology, no one knows for sure . . . . The more we 
learn about earthquakes, the more elusive real predictions seem to be.). Compare Major Storm 
Poised to Unload Snow on U.S. East Coast (Mar. 4, 2001), at http://www.cnn.com/2001/ 
WEATHER/03/03/weather.storm.02/. (U.S. East Coast residents with travel plans for Monday 
are being warned of a powerful storm moving into the region that has the potential to be the 
worst so-called noreaster in 50 years.), with Snow Across the Northeast (Mar. 6, 2001), at 
http://www.cnn.com/2001/WEATHER/03/06/winter.storms.02/index.html (A major snow-
storm traveling on the strength of a howling noreaster crept into New England overnight 
Monday into Tuesday morning, but the storm didnt pack the punch officials had expected.). 
 22. Cf. David S. Roos, Bioinformatics-Trying to Swim in a Sea of Data, 291 SCIENCE 
1260, 1261 (2001): 
The postgenomic era holds phenomenal promise for identifying the mechanistic 
bases of organismal development, metabolic processes, and disease, and we can 
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In the meantime, the development of the legal authority trails 
years, if not decades, behind.23 Given the history of such resolutions, 
the federal courts will have many years before needing to confront 
patents granted on nucleic acid discoveries with little, if any, 
corresponding genetic knowledge. Thus, no applicable precedent 
exists today. Instead, the extant decisions focus on the aspect of 
genes or gene fragments as chemical entities, and not on their 
coincidental information content.24 Indeed, a review of the most 
recent Federal Circuit cases, for example, reveals the straightforward 
consideration of genetic discoveries as chemical inventions.25 
 
confidently predict that bioinformatics research will have a dramatic impact on 
improving our understanding of such diverse areas as the regulation of gene 
expression, protein structure determination, comparative evolution, and drug 
discovery. The availability of virtually complete data sets also makes negative data 
informative: by mapping entire pathways, for example, it becomes interesting to ask 
not only what is present, but also what is absent. As the potential of genomics-scale 
studies becomes more fully appreciated, it is likely that genomics research will 
increasingly come to be viewed as indistinguishable from biology itself. But such 
research is possible only if data remain available not only for examination, but also to 
build upon. 
 23. See Lawrence M. Sung, Stranger in a Strange Land: Biotechnology and the Federal 
Circuit, 2 Wash. U. J.L. & Poly 167, 170 (2000) (noting a potential failure to appreciate the 
significant temporal distortion that exists with the decisions of the Federal Circuit in appeals 
involving biotechnology inventions and the attendant possibility that the casual observer might 
conclude the courts biotechnology judgments are senseless, because they rest on anachronistic 
notions of the science). The author explains: 
The effective date of the filing of a patent application often dictates what prior art the 
invention must overcome to qualify for patent protection. In addition, the breadth and 
depth with which applicants must describe their inventions in patent applications can 
depend upon the respective filing dates. The judicial consideration of the patentability 
of the subject matter in a patent application, or the validity of an issued patent, 
therefore must focus on the state of the art at the time of the patent application rather 
than the time of the dispute. 
The disparity between the filing of the patent application and the conclusion of the 
patent infringement lawsuit is perhaps more pronounced in the field of biotechnology 
than in the electrical, mechanical, or even chemical arts. The prosecution of 
biotechnology patent applications in the U.S. Patent & Trademark Office (USPTO) 
and the litigation of issued biotechnology patents both commonly exhibit a lengthier 
duration than that with most other types of inventions. In biotechnology matters, it is 
not uncommon for the Federal Circuit to apply the patent laws to decades-old science. 
Id. 
 24. See infra Part II.  
 25. See Ajinomoto Co. v. Archer-Daniels-Midland Co., 228 F.3d 1338 (Fed. Cir. 2000) 
(standing, oath, enablement, best mode, claim construction, infringement, importation, 
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II 
To obtain a patent, the applicant must be able to demonstrate that 
the claimed invention is useful.26 The utility of an invention, in 
concert with its novelty and nonobviousness, merits the reward of 
patent protection.27 Whether a claimed invention lacks utility is a 
question of fact, which the Federal Circuit reviews under the clearly 
erroneous standard.28 In any event, an alleged inventive act is not 
legally cognizable unless the inventor conceived of the specific utility 
of the claimed invention.29 
In Kridl v. McCormick,30 the Federal Circuit addressed the utility 
requirement in the context of a patent interference proceeding.31 The 
court reviewed the determination of the USPTO Board of Patent 
Appeals and Interferences (Board), which considered two competing 
patent applications claiming the same, or substantially the same, 
biotechnology subject matter.32 The interference count related to the 
use of antisense technology to produce plants or plant cells with 
 
damages); SIBIA Neurosciences, Inc. v. Cadus Pharm. Corp., 225 F.3d 1349 (Fed. Cir. 2000) 
(obviousness); Life Techs., Inc. v. Clontech Labs., Inc., 224 F.3d 1320 (Fed. Cir. 2000) 
(inequitable conduct, prior inventorship); Singh v. Brake, 222 F.3d 1362 (Fed. Cir. 2000) 
(conception, written description, enablement); Schering Corp. v. Amgen Inc., 222 F.3d 1347 
(Fed. Cir. 2000) (claim construction); Genentech, Inc. v. Chiron Corp., 220 F.3d 1345 (Fed. 
Cir. 2000) (conception); Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362 (Fed. Cir. 1999) 
(enablement, experimental use). 
 26. See 35 U.S.C. § 101 (1994) (Whoever invents or discovers any new and useful 
process, machine, manufacture, or composition of matter, or any new and useful improvement 
thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.). 
 27. Brenner v. Manson, 383 U.S. 519, 534 (1966) (The basic quid pro quo contemplated 
by the Constitution and the Congress for granting a patent monopoly is the benefit derived by 
the public from an invention with substantial utility.); Cross v. Iizuka, 753 F.2d 1040, 1044 
(Fed. Cir. 1985). 
 28. See Raytheon Co. v. Roper Corp., 724 F.2d 951, 956 (Fed. Cir. 1983). 
 29. See Rey-Bellet v. Engelhardt, 493 F.2d 1380, 1385 (C.C.P.A. 1974) ([C]onception of 
an invention is not complete absent a conception of its utility.). 
 30. 105 F.3d 1446 (Fed. Cir. 1997). 
 31. Id. at 1447. The USPTO may declare an interference where a patent application claims 
the same, or substantially the same, subject matter as another application or as an unexpired 
patent. See 35 U.S.C. § 135 (1994). In this proceeding, the USPTO determines which party has 
priority of invention, or in other words, who was the first to invent. Because the first to invent is 
the only true inventor entitled to patent protection, the outcome of an interference proceeding 
typically leaves the winner with a patent and the loser without. 
 32. 105 F.3d at 1448 (reporting the interference declared between a patent application 
assigned to Agracetus, Inc., and another assigned to Calgene, Inc.). 
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resistance to certain viruses.33 McCormick, having filed a patent 
application before Kridl, was the first to reduce the invention to 
practice, albeit constructively.34 To establish priority of invention, 
however, McCormick also needed to prove a date of conception 
before that of Kridl.35 
McCormick sought to rely upon the pages of Marcia Vincents 
laboratory notebook.36 These pages described an experiment in 
January 1984 in which a gene fragment encoding a viral protein was 
inserted into a cloning vector in both the sense and antisense 
orientations.37 The Board applied a rule of reason analysis to 
evaluate this evidence and found that McCormick conceived of the 
invention before Kridl.38 The Board thus awarded priority of 
invention to McCormick.39 
In reaching its decision, the Board also concluded that 
McCormick conceived of the utility of the claimed invention in 
January 1984.40 The Board did so based solely on the uncorroborated 
testimony of one of the inventors, Dr. William Swain.41 Kridl 
contended that antisense had more than one substantial use, and thus, 
McCormick might have used it for a different purpose in January 
1984.42 According to Kridl, McCormick could have used antisense as 
an experimental control or as a mere template for the production of 
recombinant DNA in the sense orientation.43 
The Federal Circuit considered the state of the biotechnology art 
in 1984 to refute Kridls arguments and affirm the Boards 
 
 33. See id. An interference count establishes the scope of the interference by defining the 
invention common to the parties. The interpretation of an interference count is analogous to 
claim construction. 
 34. See id. at 1449. 
 35. See id. 
 36. See id. at 1448. 
 37. See id. at 1448-49. 
 38. See id. at 1449; see also Price v. Symsek, 988 F.2d 1187, 1195 (Fed. Cir. 1993) (A 
rule of reason analysis is applied to determine whether the inventors prior conception 
testimony has been corroborated . . . . An evaluation of all pertinent evidence must be made so 
that a sound determination of the credibility of the inventors story may be reached.). 
 39. See Kridl, 105 F.3d at 1449, 1688. 
 40. See id. 
 41. See id. at 1450. 
 42. See id. 
 43. See id. 
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determination.44 There was no dispute that the use of antisense in 
plants was not known in 1984.45 The Federal Circuit thus reasoned 
that it would have been illogical for McCormick to use such novel 
material as an experimental control, which usually involves tried and 
true compounds.46 In addition, because sense constructs could be 
produced at that time by more established methods, the Federal 
Circuit stated that it would have been wasteful for anyone to use 
antisense to generate recombinant DNA in the sense orientation.47 
Accordingly, the Federal Circuit held that an individual skilled in 
the art in 1984 would have seen no other substantial use for the 
antisense constructs described in Ms. Vincents laboratory notebook 
than as a means for imparting viral resistance to plants or plant 
cells.48 The court stated that under a rule of reason analysis, explicit 
corroboration of the inventors recognition of utility might not always 
be necessary.49 For example, in certain situations, utility might be 
implicit in the evidence presented.50 
Similar to the biotechnology cases involving obviousness 
inquiries, the Federal Circuit in Kridl was forced to rely on its 
hindsight analysis of the state of the art as the context for the parties 
conduct. Indeed, in Kridl, the look backwards crossed almost a 
decade and a half. This practice only further complicates the already 
difficult task before the Federal Circuit in parsing unfamiliar 
technology. The genomics, bioinformatics, and proteomics arts will 
likely face similar difficulties. 
To receive patent protection, an invention must be nonobvious at 
the time of the invention to one of ordinary skill in the relevant art.51 
Nonobviousness is a question of law that the Federal Circuit reviews 
de novo.52 The conclusion of nonobviousness, however, is subject to 
underlying factual findings, which the Federal Circuit reviews for 
 
 44. See id. 
 45. See id. 
 46. See id. 
 47. See id. 
 48. See id. 
 49. See id. at 1451. 
 50. See id. 
 51. See 35 U.S.C. § 103 (1994) (defining conditions for patentability, including 
nonobvious subject matter). 
 52. See In re Donaldson Co., 16 F.3d 1189, 1192 (Fed. Cir. 1994) (en banc). 
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clear error.53 
During patent prosecution, the patent examiner bears the burden 
of establishing a prima facie case of obviousness.54 Once the 
examiner meets this initial burden, the burden shifts to the applicant 
to provide rebuttal evidence to overcome the examiners rejection.55 
In In re Deuel,56 the Federal Circuit reversed the Boards decision, 
which upheld the patent examiners final rejection of the claims as 
obvious.57 The subject matter of the application involved DNA 
encoding heparin-binding growth factor (HBGF) of bovine and 
human origins.58 Deuel first isolated bovine uterine HBGF protein 
and determined the amino acid sequence of a small beginning portion 
of the protein.59 Next, Deuel chemically synthesized a single strand 
of DNA (oligonucleotide) corresponding to this short amino acid 
sequence.60 Using this oligonucleotide, Deuel isolated the naturally 
occurring bovine HBGF gene from a collection of DNAs (cDNA 
library) encoding bovine uterine proteins in general.61 Deuel then 
determined the entire nucleotide sequence of the bovine uterine 
HBGF gene and predicted the amino acid sequence of the remaining 
unknown portion of the bovine uterine HBGF protein.62 These bovine 
sequences constituted part of the claimed invention.63 
In addition, Deuel used the oligonucleotide to isolate the naturally 
occurring human HBGF gene from the human placental cDNA 
library.64 Similarly, Deuel then determined the entire nucleotide 
 
 53. See In re Woodruff, 919 F.2d 1575, 1577 (Fed. Cir. 1990); see also In re Beattie, 974 
F.2d 1309, 1311 (Fed. Cir. 1992) (discussing what the prior art teaches as a question of fact 
reviewable under the clearly erroneous standard). 
 54. See In re Rijckaert, 9 F.3d 1531, 1532 (Fed. Cir. 1993). 
 55. See id.; see also In re Dillon, 919 F.2d 688, 692-93 (Fed. Cir. 1990) (en banc) (Such 
rebuttal or argument can consist of . . . any other argument or presentation of evidence that is 
pertinent.), cert. denied, 500 U.S. 904 (1991). 
 56. 51 F.3d 1552 (Fed. Cir. 1995). 
 57. In re Deuel, 51 F.3d 1552, 1554 (Fed. Cir. 1995), rev’g ex parte, 33 U.S.P.Q.2d 
(BNA) 1445 (Bd. Pat. App. & Interferences 1993). 
 58. 51 F.3d at 1554. The application at issue was U.S. Application Serial No. 07/542,232. 
Id. at 1553. 
 59. Id. at 1555. 
 60. Id. 
 61. Id. 
 62. Id. 
 63. Id. 
 64. Id. 
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sequence of the human placental HBGF gene and predicted the amino 
acid sequence of the complete human placental HBGF protein.65 
These human sequences also constituted part of the claimed 
invention.66 
The patent examiner asserted that the claimed invention would 
have been prima facie obvious in view of the prior art.67 The prior art 
upon which the examiner relied included a reference (Maniatis) 
describing gene cloning methods and a reference (Bohlen) disclosing 
the partial amino acid sequences of proteins composing a subclass of 
human and bovine HBGF.68 The examiner maintained that Bohlen 
would have motivated one skilled in the art to clone the respective 
human and bovine HBGF genes according to Maniatis to produce 
human and bovine HBGF protein.69 
In rebuttal, Deuel contended that the prior art taught away from 
the claimed invention. According to Deuel, Bohlen suggested that 
one skilled in the art would not have been motivated to use the same 
oligonucleotide to isolate the genes for human and bovine HBGF.70 
The examiner rejected Deuels teaching away argument, apparently 
relying on the unfounded notion that HBGF genes were homologous 
across species.71 The Board upheld the examiners rejection, focusing 
instead on the allegedly routine nature of cloning.72 
In reversing the rejection of Deuels claims, the Federal Circuit 
relied on precedent stating that, absent prior art suggesting the 
specific claimed DNA, a particular DNA sequence is not obvious 
simply because the prior art discloses general methods for isolating 
DNA.73 The court further applied precedent regarding chemical 
inventions stating that the prior art disclosure of a broad genus does 
not necessarily render obvious a specific compound within the 
genus.74 Because many different DNA sequences can encode the 
 
 65. Id. 
 66. Id. 
 67. Id. at 1555. 
 68. Id. at 1555-56. 
 69. Id. at 1556. 
 70. Id. 
 71. Id. 
 72. Id. at 1556-57. 
 73. Id. at 1559 (affirming In re Bell, 991 F.2d 781, 785 (Fed. Cir. 1993)). 
 74. 51 F.3d at 1559 (citing with approval In re Baird, 16 F.3d 380 (Fed. Cir. 1994)). 
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identical protein, the court concluded that the simple disclosure of the 
protein does not render any particular one of those DNA sequences 
obvious, absent prior art specifically pointing to one sequence.75 The 
Federal Circuit also discounted the Boards contentions regarding the 
routine nature of Deuels work as mere speculation and 
impermissible hindsight reconstruction of the claimed invention.76 
Obviousness inquiries in all technologies risk corruption from the 
hindsight analysis method.77 The long time-lapse between patent 
application filing and litigation with biotechnology inventions can 
exacerbate the problem.78 The often unsettled nature of science, 
compounded with the natural deterioration of reliable accounts of that 
context, make invalidity challenges to biotechnology patents based 
on obviousness unpredictable, notwithstanding the statutory 
presumption of validity. When considering genomics, bioinformatics, 
and proteomics inventions in the future, the courts will likely 
confront similar problems in resolving obviousness questions. 
As an additional requirement for patent protection, an inventor 
must set forth an adequate written description of the invention.79 In 
short, a patent must describe an invention in sufficient detail that one 
skilled in the art could clearly conclude that the inventor had 
possession of the claimed subject matter.80 For biotechnology 
inventions, an adequate written description of nucleic acids, such as 
DNA or RNA, requires a precise definition, including the pertinent 
structure, formula, chemical name, or physical properties.81 A mere 
statement that a nucleic acid is part of the invention, and a reference 
 
 75. 51 F.3d at 1558-59. 
 76. Id. at 1558. 
 77. See In re Dembiczak, 175 F.3d 994, 999 (Fed. Cir. 1999). 
Measuring a claimed invention against the standard established by section 103 requires 
the oft-difficult but critical step of casting the mind back to the time of invention, to 
consider the thinking of one of ordinary skill in the art, guided only by the prior art 
references and the then-accepted wisdom in the field. 
Id. 
 78. See, e.g., supra note 23 and accompanying text.  
 79. See 35 U.S.C. § 112 (1994). 
 80. See Lockwood v. Am. Airlines, Inc., 107 F.3d 1565, 1572 (Fed. Cir. 1997); In re 
Gosteli, 872 F.2d 1008, 1012 (Fed. Cir. 1989). 
 81. See Fiers v. Revel, 984 F.2d 1164, 1171 (Fed. Cir. 1993). 
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to a potential method for isolating it, will not suffice.82 
In In re Brana,83 the Federal Circuit reversed the Boards decision 
that upheld the patent examiners final rejection of the claims of the 
application for failure to satisfy the written description requirement.84 
The subject matter of the application involved pharmaceutical 
compositions having antitumor activity in humans.85 In the final 
office action, the examiner rejected the claims of the application, 
because the specification failed to describe any specific disease 
against which the claimed compounds were active and did not 
establish a reasonable expectation that the claimed compounds had a 
practical utility.86 The Board upheld the patent examiners rejection 
under § 112, first paragraph, but stated that a rejection under § 101 
would likewise have been proper.87 
Regarding the examiners written description, the Federal Circuit 
noted that the applicants tested the claimed compounds on tumor cell 
lines derived from animals suffering from lymphocytic leukemias.88 
The court thus concluded that the disclosed ameliorative activity of 
the claimed compounds on tumor cells constituted a proper allegation 
of sufficiently specific use.89 As for the utility rejection, the Federal 
Circuit held that the examiner failed to satisfy the initial burden of 
challenging a presumptively correct assertion of utility in the 
disclosure.90 The court noted that the prior art references upon which 
the Board relied did not question the usefulness of any related 
compound as an antitumor agent.91 Moreover, one of the references 
disclosed compounds that were structurally similar to those of the 
claimed invention and possessed proven in vivo effectiveness as 
chemotherapeutics against various types of tumors.92 The Federal 
 
 82. See id. at 1170. The adequacy of a written description is a question of fact that the 
Federal Circuit reviews for clear error. See Ralston Purina Co. v. Far-Mar-Co, Inc., 772 F.2d 
1570, 1575 (Fed. Cir. 1985). 
 83. 51 F.3d 1560 (Fed. Cir. 1995). 
 84. Id. at 1569.  
 85. See id. at 1562 (citing the U.S. patent application as Serial No. 533,944). 
 86. See id. at 1563-64. 
 87. See id. at 1564. 
 88. See id. at 1565. 
 89. See id. 
 90. See id. at 1566. 
 91. See id. 
 92. See id. 
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Circuit held that even if the USPTO satisfied its initial burden, the 
applicants evidence of statistically significant results from animal 
tests was sufficient to convince one skilled in the art of the 
inventions asserted utility.93 
In Fiers v. Revel,94 the Federal Circuit affirmed the Boards 
decision toward priority of invention to Sugano et al.95 The 
interference amongst three foreign inventive entities (Fiers, Revel, 
and Sugano) related to the DNA that coded for human fibroblast 
beta-interferon (β-IF), a protein that promotes viral resistance in 
human tissue.96 The Board based its decision on the findings that (i) 
Sugano was entitled to the benefit of the March 19, 1980 filing date 
of its Japanese patent application; (ii) Fiers was entitled to the benefit 
of the April 3, 1980 filing date of its British patent application, but 
failed to prove conception of the subject matter before that date; and 
(iii) Revel was not entitled to the benefit of the November 21, 1979 
filing date of its Israeli patent application.97 
The Federal Circuit upheld the Boards determinations, noting that 
 
 93. See id. at 1567. The court also noted that to require in vivo human testing akin to 
Phase II clinical studies conducted by the Food and Drug Administration would place a higher 
standard § 112, ¶ 1, compliance on applicants seeking patent protection for pharmaceuticals for 
humans. 
 94. 984 F.2d 1164 (Fed. Cir. 1993). 
 95. Id. at 1166.  
 96. See id. at 1166 (reporting the interference count defined as [a] DNA which consists 
essentially of a DNA which codes for a human fibroblast interferon-beta polypeptide). 
 97. See id. at 1167. 
Suganos Japanese application disclosed the complete nucleotide sequence of a DNA 
coding for β-IF and a method for isolating that DNA. Revels Israeli application 
disclosed a method for isolating a fragment of the DNA coding for B-IF as well as a 
method for isolating messenger RNA (mRNA) coding for β-IF, but did not disclose a 
complete DNA sequence coding for β-IF. Fiers, who was working abroad, based his 
case for priority on an alleged conception either in September 1979 or in January 1980, 
when his ideas were brought into the United States, coupled with diligence toward a 
constructive reduction to practice on April 3, 1980, when he filed a British application 
disclosing the complete nucleotide sequence of a DNA coding for β-IF. According to 
Fiers, his conception of the DNA of the count occurred when two American scientists, 
Walter Gilbert and Phillip Sharp, to whom he revealed outside of the United States a 
proposed method for isolating DNA coding for β-IF brought the protocol back to the 
United States . . . . On February 26, 1980, Fiers patent attorney brought into the 
United States a draft patent application disclosing Fiers method, but not the nucleotide 
sequence for the DNA. 
Id. 
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when an inventor is unable to envision the detailed chemical 
structure of the gene so as to distinguish it from other materials, as 
well as a method for obtaining it, conception has not been achieved 
until reduction to practice has occurred, i.e., until after the gene has 
been isolated.98 The court thus held that irrespective of the 
complexity or simplicity of the method of isolation employed, 
conception of a DNA, like conception of any chemical substance, 
requires a definition of that substance other than by its functional 
utility.99 
The Federal Circuit concluded that Fiers proof of conception of a 
method that enabled one of ordinary skill in the art to make the DNA 
of the count was insufficient to establish conception of the DNA 
count.100 In addition, the court held that Revel failed to prove that its 
Israeli patent application contained a written description of a DNA 
coding for β-IF because it did not disclose the nucleotide sequence or 
an intact complete gene.101 By contrast, Suganos Japanese patent 
application set forth the complete and correct nucleotide sequence of 
a DNA coding for β-IF, thus satisfying the written description 
 
 98. See id. at 1168-69 (quoting Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 
(Fed. Cir. 1991)). 
 99. See id. at 1169. 
 100. See id.  
Before reduction to practice, conception only of a process for making a substance, 
without a conception of a structural or equivalent definition of that substance, can at 
most constitute a conception of the substance claimed as a process. Conception of a 
substance claimed per se without reference to a process requires conception of its 
structure, name, formula, or definitive chemical or physical properties. 
Id. 
 101. See id. at 1170-71. 
An adequate written description of a DNA requires more than a mere statement that it 
is part of the invention and reference to a potential method for isolating it; what is 
required is a description of the DNA itself. Revels specification does not do that. 
Revels application does not even demonstrate that the disclosed method actually leads 
to the DNA, and thus that he had possession of the invention, since it only discloses a 
clone that might be used to obtain mRNA coding for β-IF. A bare reference to a DNA 
with a statement that it can be obtained by reverse transcription is not a description; it 
does not indicate that Revel was in possession of the DNA. Revels argument that 
correspondence between the language of the count and language in the specification is 
sufficient to satisfy the written description requirement is unpersuasive when none of 
that language particularly describes the DNA. 
Id. 
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requirement and entitling Sugano to the benefit of that foreign filing 
date.102 
In University of California v. Eli Lilly & Co.,103 the Federal 
Circuit affirmed the district courts judgment that the asserted patent 
claims were invalid because the patent failed to provide an adequate 
written description of the claimed subject matter.104 The patented 
technology involved human insulin produced by recombinant DNA 
methods.105 
The patent claims were directed to the use of human insulin 
cDNA, but the specification provided a written description only 
regarding rat insulin cDNA.106 Although the patent recited a general 
method for obtaining human cDNA, along with the amino acid 
sequences for human insulin, the Federal Circuit noted that 
enablement was not the issue.107 This disclosure provided no 
structural information or physical characteristics, such as a nucleotide 
sequence, of any of the human cDNAs in the claimed genus.108 
Absent such identification, the generic references to vertebrate or 
mammalian insulin cDNA were inadequate written descriptions, 
which could not be used to distinguish the claimed genus from others, 
except by function.109 The Federal Circuit stated that a proper written 
description of a cDNA genus, for example, might be the nucleotide 
sequences of a representative number of cDNAs, or the recitation of 
structural features common to the members of the genus.110 Generic 
references alone indicate only what one might achieve and provide no 
information about the resulting claimed material.111 
The pronouncements on written description by the Federal Circuit 
 
 102. See id. at 1172 (stating that Suganos Japanese patent application convey[s] with 
reasonable clarity to those skilled in the art that, as of the filing date sought, [Sugano] was in 
possession of the [DNA coding for β-IF]). 
 103. 119 F.3d 1559 (Fed. Cir. 1997), cert. denied, 523 U.S. 1089 (1998). 
 104. Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1562 (Fed. Cir. 1997), cert. denied, 
523 U.S. 1089 (1998). 
 105. See id. (identifying the patents-in-suit as U.S. Patents No. 4,652,525 (issued Mar. 24, 
1987) and No. 4,431,740 (issued Feb. 14, 1984)). 
 106. See id. at 1562-63. 
 107. See id. at 1567. 
 108. See id. 
 109. See id. 
 110. See id. at 1568. 
 111. See id. 
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arguably garnered more criticism than any other statutory compliance 
issue in recent days. With biotechnology subject matter involving 
molecular genetic information, the Federal Circuit has clearly taken 
an extreme position in requiring the disclosure of actual nucleotide 
sequences as claim support.112 The ideological controversy about the 
origins and justifications of the written description requirement aside, 
the Federal Circuit holding in Eli Lilly creates a serious question as to 
the continuing vitality of prophetic patent claims, certainly with 
respect to biotechnology inventions, if not others as well. 
Since Eli Lilly, the Federal Circuit seems to have opened the door 
to a more liberal interpretation of the written description requirement 
vis-à-vis the state of the relevant technology.113 In Union Oil, the 
Federal Circuit arguably refines the written description inquiry to 
shift the focus of the determination away from the isolated disclosure 
and closer to what those skilled in the art could understand from that 
disclosure.114 Accordingly, even if the Federal Circuit were to stand 
firmly behind its earlier pronouncements on written description in 
other respects, the rapidly changing state of biotechnology should 
eventually alleviate the seemingly harsh results possible from the Eli 
Lilly standard alone. Following the reasoning of Union Oil, the 
 
 112. See, e.g., Janice M. Mueller, The Evolving Application of the Written Description 
Requirement to Biotechnological Inventions, 13 BERKELEY TECH. L.J. 615, 617 (1998). 
The Lilly decision establishes uniquely rigorous rules for the description of 
biotechnological subject matter that significantly contort written description doctrine 
away from its historic origins and policy grounding. The Lilly courts elevation of 
written description to an effective super enablement standard of uncertain scope and 
applicability will likely chill development in this critically important technological 
field and frustrate the United States patent systems policy goal of encouraging prompt 
disclosure of new inventions. 
Id. 
 113. See Union Oil Co. of Cal. v. Atlantic Richfield Co., 208 F.3d 989, 997 (Fed. Cir. 
2000). 
Appellant refiners assert that the specification does not describe the exact chemical 
component of each combination that falls within the range claims of the 393 patent. 
However, neither the Patent Act nor the case law of this court requires such detailed 
disclosure. Rather, the Patent Act and this courts case law require only sufficient 
description to show one of skill in the refining art that the inventor possessed the 
claimed invention at the time of filing.  
Id. (internal citations omitted). 
 114. Id.  
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disclosure of actual nucleotide sequences should not be required as 
claim support once the state of biotechnology advances to the point at 
which those skilled in the art could understand that, in the absence of 
such disclosure, the inventor was in possession of the claimed 
invention at the time of application filing. 
III 
As the foregoing section indicated, the existing legal authority 
provides little guidance regarding the genomics, bioinformatics, and 
proteomics inventions that the USPTO faces today. Indeed, if the 
time from filing a patent application, to federal court judgments, with 
respect to past biotechnology patent cases, is any indication, it will be 
several years before the Federal Circuit sees such matters. 
Accordingly, because Federal Circuit precedent does not answer the 
question of whether nucleic acid discoveries with little, if any, 
corresponding genetic knowledge are patentable, the USPTO is 
forced to consider the issue first, without guidance. 
In February 1997, the USPTO adopted a controversial position 
when it announced the likely grant of patent claims to ESTs and 
SNPs, despite minimal disclosure of their biological significance by 
the patent applicant.115 The patent claims receiving the preliminary 
approval of the USPTO seemed of such broad scope that even the use 
of products derived from genetic material, of which only a fraction of 
the sequence is patented, could constitute an infringement under the 
patent law.116 The patent applicant ultimately withdrew these 
claims.117 Nonetheless, such claims fueled already mounting public 
outcry over gene patenting, which spurred the USPTO into action.118 
On January 5, 2001, the USPTO issued examination guidelines on 
the patentability requirements of utility and written description.119 
This action marked a significant retreat from the questionable policy 
 
 115. See Ed Susman, U.S. PTO to Allow Patents on Gene Fragments called ESTs, 
BIOTECHNOLOGY NEWSWATCH, Mar. 3, 1997, at 1; Lynn Pasahow & Andrew Kumamoto, 
Human Genome Project Raises Patenting Issues, NATL L.J., Oct. 20, 1997, at C31. 
 116. See Susman, supra note 115, at 1. 
 117. See id. 
 118. See Pasahow & Kumamato, supra note 115, at C31. 
 119. See infra notes 120-23. 
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decision by the USPTO in 1997. Moreover, this consideration 
appears to end an almost four-year moratorium on the issuance of 
patent claims to ESTs and SNPs. 
At the outset, the utility examination guidelines provided 
responses to comments generated by earlier proposed versions of the 
guidelines.120 Although generally applicable to all technologies, these 
guidelines reacted to public concerns about the patenting of ESTs and 
SNPs.  
The USPTO acknowledged that patent claims to ESTs and SNPs, 
or any other nucleic acids, are unpatentable for lack of utility where 
the supporting disclosure fails to provide any information regarding a 
biological association or function corresponding to the claimed 
nucleic acid.121 According to the USPTO, only in conjunction with 
such a teaching would a claimed nucleic acid have a specific, 
substantial, and credible utility.122 
Like the utility examination guidelines, the revised written 
description guidelines provided responses to comments generated by 
earlier proposed versions.123 As with the utility examination 
guidelines, the written description guidelines promulgated in reaction 
to public concerns about the patenting of ESTs and SNPs, despite the 
disclaimer of their general applicability to all technologies.  
Arguably less provocative than the utility examination guidelines 
 
 120. See Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 6, 2001) (This revision 
supersedes the Revised Interim Utility Examination Guidelines that were published at 64 FR 
71440, Dec. 21, 1999; 1231 O.G. 136 (2000); and correction at 65 FR 3425, Jan. 21, 2000; 
1231 O.G. 67 (2000).). 
 121. See id. at 1093. 
If a patent application discloses only nucleic acid molecular structure for a newly 
discovered gene, and no utility for the claimed isolated gene, the claimed invention is 
not patentable. [W]here the application discloses a specific, substantial, and credible 
utility for the claimed isolated and purified gene, the isolated and purified gene 
composition may be patentable.  
Id.  
 122. Id.  
 123. See Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1, 
Written Description Requirement, 66 Fed. Reg. 1099 (Jan. 6, 2001) (These Guidelines 
supersede the Revised Interim Guidelines for Examination of Patent Applications Under the 
35 U.S.C. 112, ¶ 1 Written Description Requirement that were published in the Federal 
Register at 64 FR 71427, Dec. 21, 1999, and in the Official Gazette at 1231 O.G. 123, Feb. 29, 
2000.). 
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with respect to the patenting of ESTs and SNPs, the written 
description guidelines tracked Federal Circuit precedent closely.124 In 
this regard, the USPTO reiterated that patent claims to a nucleic acid 
drawn only by reference to its biological association or function, 
where the supporting disclosure provides no understanding of the 
chemical structure of the nucleic acid (such as the nucleotide 
sequence), would be unpatentable for lack of adequate written 
description.125 In short, patent protection would extend only to those 
inventions involving nucleic acids for which the patent applicants 
provided the public with both a proper understanding of the structure 
of the claimed nucleic acids, and the corresponding genetic 
knowledge they contained.126 
IV 
The Federal Circuit and its predecessor court expressed the 
necessity of those seeking a patent grant to provide the public with 
appropriate notice of the metes and bounds of their inventions and 
attendant exclusive rights.127 Similarly, the courts demanded that 
patent applicants be clear about their claimed inventions with respect 
to their required disclosures.128 
 
 124. A biomolecule sequence described only by a functional characteristic, without any 
known or disclosed correlation between that function and the structure of the sequence, 
normally is not a sufficient identifying characteristic for written description purposes, even 
when accompanied by a method of obtaining the claimed sequence. For example, even though a 
genetic code table would correlate a known amino acid sequence with a genus of coding nucleic 
acids, the same table cannot predict the native, naturally occurring nucleic acid sequence of a 
naturally occurring mRNA or its corresponding cDNA. The Federal Circuit pointed out that 
under U.S. law, a description that does not render a claimed invention obvious cannot 
sufficiently describe the invention for the purposes of the written description requirement of 35 
U.S.C. § 112. See Guidelines for Examination of Patent Applications Under the 35 U.S.C. 
§ 112, 711, Written Description Requirement, 66 Fed. Reg. at 1108 n.14. 
 125. Id.  
 126. Id.  
 127. See Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 234 F.3d 558, 575 
(Fed. Cir. 2000) ([T]he notice function of patent claims has become paramount, and the need 
for certainty as to the scope of patent protection has been emphasized.), cert. granted, 69 
U.S.L.W. 3779 (No. 00-1543) (U.S. June 18, 2001); see also infra note 128 and accompanying 
text (describing the significance of notice and guidance with respect to the written description 
requirement).  
 128. It is an old custom in the woods to mark trails by making blaze marks on the trees. It 
is no help in finding a trail . . . to be confronted simply by a large number of unmarked trees. 
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Promulgated in view of these Federal Circuit precedents, the 
recent rules set forth by the USPTO on the patentability standards of 
utility and written description, establish the need for the analogous 
degree of clarity in genetic discoveries and other biotechnology 
inventions.129 However, the USPTO appears to recognize that 
inventions involving nucleic acids possess distinct characteristics or 
structure and function that cannot be easily divorced from one 
another.130 
Although the forecast for judicial treatment of this technology 
might not be an optimistic one, it might be fair to say that any stormy 
weather should pass. Indeed, the resolution might owe as much to the 
progress of the science as it will to action by the USPTO and federal 
courts in governing the science. 
The likelihood exists that as increased competency in computer 
predictive modeling develops in bioinformatics and proteomics, a 
bare nucleotide sequence can reveal its biological significance. We 
should have every reason to trust that the isolation today of an 
otherwise nonsensical sequence of nucleotides will soon be 
supplanted by technology that simultaneously identifies a multiplicity 
of inherent characteristics that can perhaps indicate, inter alia, origin, 
function, and evolutionary lineage. As the state of the art achieves 
this hope, the patent system might find its treatment of such 
inventions in the future easier to reconcile than suspected today. 
 
In re Ruschig, 379 F.2d 990, 994-95 (C.C.P.A. 1967), quoted in Fujikawa v. Wattanasin, 93 
F.3d 1559, 1570 (Fed. Cir. 1996). 
 129. See supra notes 120-23 and accompanying text (discussing USPTO guidelines). 
 130. A DNA sequencei.e., the sequence of base pairs making up a DNA moleculeis 
simply one of the properties of a DNA molecule. Like any descriptive property, a DNA 
sequence itself is not patentable. A purified DNA molecule isolated from its natural 
environment, on the other hand, is a chemical compound and is patentable if all the statutory 
requirements are met. An isolated and purified DNA molecule may meet the statutory utility 
requirement if, e.g., it can be used to produce a useful protein or it hybridizes near and serves as 
a marker for a disease gene. Therefore, a DNA molecule is not per se unpatentable for lack of 
utility, and each application claim must be examined on its own facts. Utility Examination 
Guidelines, 66 Fed. Reg. 1092, 1094 (Jan. 6, 2001).  
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CONCLUSION 
The release of the completed nucleotide sequence of the human 
genome represents the culmination of extraordinary efforts to 
demystify a fundamental question of who we are. The close of this 
phase of scientific endeavor, however, finds itself at the dawn of new 
progress towards comprehending the daunting volumes of genetic 
data the Human Genome Project uncovered. Bioinformatics and 
proteomics are such fields of research that will rise with the wave that 
the genomics surge started. 
Ownership of genetic discoveries is not a new occurrence. 
However, what is troubling for many is the developing possibility of 
patent protection for inventions involving nucleic acids with minimal, 
if any, teaching regarding the biological significance. The present 
controversy over patenting genes and gene fragments seems more 
principled where a patent applicant fails to couple genetic knowledge 
with the disclosure of the chemical structure of the claimed nucleic 
acid. 
The legal authority that will likely frame these issues focuses on 
the utility and written description requirements under the patent law. 
Applying existing case law, the USPTO and Federal Circuit should 
take the position that a patent claim to a bare nucleotide sequence, 
devoid of any indication of biological association or function, lacks 
utility. Similarly, a patent claim to a desired biological association or 
function, without the disclosure of a specific nucleic acid as defined 
by its nucleotide sequence, is not supported by an adequate written 
description. Under this interpretation of the statutory scheme, the 
patentability of a nucleic acid would depend upon a proper disclosure 
reflecting the merger between its characteristics as a chemical 
compound and a storage medium for biological information. 
As the fields of bioinformatics and proteomics develop, the 
separation between strategies of the past in patenting genes and gene 
fragments, and the agendas of the present and future in patenting 
ESTs and SNPs might begin to close. Where computer predictive 
modeling through bioinformatics and proteomics can provide 
meaning in the sense of biologic significance based on the nucleotide 
sequence alone, the public can begin to obtain the clearer knowledge 
benefit it demands in exchange for granting a temporary right of 
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exclusivity to the discoverer of the claimed nucleic acid. To the 
extent this convergence fails to occur, the USPTO and the federal 
courts must be mindful of the problematic consequences that can 
arise from approving or upholding patent claims where the 
supporting disclosure teaches only the nucleotide sequence of the 
nucleic acid, or only the biological association and function of the 
nucleic acid, but not both. Allowing and enforcing such claims in 
those circumstances would constitute an unreasonable extension of 
the patent right. 
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